The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its future within the broader industry now presents questions about potential gains. Copycat versions are eroding exclusivity , leading to concerns that investing in companies closely tied to Viagra's previous standing could be a speculative move